Hiroshi Yaegashi
Overview
Explore the profile of Hiroshi Yaegashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
314
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hori T, Iwamoto H, Makino T, Naito R, Yaegashi H, Kawaguchi S, et al.
Cureus
. 2025 Feb;
17(1):e77300.
PMID: 39935910
Background: Castration-resistant prostate cancer (CRPC) represents a significant difficulty in oncology, with limited treatment options and decreasing survival rates. The comprehensive genomic profiling (CGP) test has appeared as a promising...
2.
Furukawa J, Kato T, Yamasaki T, Monji K, Tanaka T, Tsuchiya N, et al.
Int J Clin Oncol
. 2025 Feb;
PMID: 39934514
Background: Avelumab + axitinib was approved for the treatment of advanced renal cell carcinoma (aRCC) in Japan in December 2019. We report long-term real-world subgroup analyses with first-line avelumab + ...
3.
Makino T, Sakurai T, Takamatsu S, Kano H, Naito R, Iwamoto H, et al.
Sci Rep
. 2025 Feb;
15(1):5118.
PMID: 39934343
We evaluated the long-term treatment outcomes and toxicities in patients with clinically localized and locally advanced prostate cancer (PC) who underwent high-dose-rate brachytherapy (HDR-BT) with external beam radiotherapy (EBRT). We...
4.
Nakagawa R, Izumi K, Toriumi R, Aoyama S, Kano H, Makino T, et al.
Int J Clin Oncol
. 2025 Jan;
30(3):524-531.
PMID: 39827245
Background: Enfortumab vedotin (EV) is a novel treatment for metastatic urothelial carcinoma (mUC) that progresses after platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy. This study aimed to compare the efficacy of...
5.
Nakagawa R, Izumi K, Hiratsuka K, Inaba T, Koketsu Y, Toriumi R, et al.
Neoplasia
. 2024 Dec;
60:101103.
PMID: 39700633
We investigated the mechanisms of interaction between bladder cancer (BC) cells and tumor-associated macrophages (TAMs). Coculturing BC cell lines (UMUC3 and T24) with macrophage-like cells differentiated from THP-1 into M2-like...
6.
Yaegashi H, Izumi K, Makino T, Naito R, Iwamoto H, Kawaguchi S, et al.
Cureus
. 2024 Oct;
16(9):e69366.
PMID: 39398648
Objectives Microsatellite instability-high (MSI-H) and high tumor mutation burden (TMB-high) frequencies were investigated to determine the efficacy and adverse events of pembrolizumab in patients with urologic malignancies (or their equivalents)...
7.
Iwamoto H, Hori T, Nakagawa R, Kano H, Makino T, Naito R, et al.
Cancers (Basel)
. 2024 Sep;
16(18).
PMID: 39335169
Background: The treatment strategy for metastatic castration-sensitive prostate cancer (mCSPC) has changed significantly in recent years. Based on various guidelines, an upfront androgen receptor signaling inhibitor (ARSI) is the first...
8.
Nakagawa R, Izumi K, Toriumi R, Aoyama S, Kamijima T, Kano H, et al.
Jpn J Clin Oncol
. 2024 Jul;
54(12):1329-1335.
PMID: 39077841
Objectives: Enfortumab vedotin (EV) is an established pharmacotherapy for metastatic urothelial carcinoma (mUC); however, its adverse events (AEs) cannot be overlooked. The study investigated the efficacy and safety of biweekly...
9.
Nohara T, Takimoto A, Shinzawa R, Kurauchi D, Toriumi R, Nakagawa R, et al.
Int J Urol
. 2024 Apr;
31(8):891-898.
PMID: 38687138
Objective: Intraoperative hypotension remains a serious adverse event of photodynamic diagnosis-assisted transurethral resection of bladder tumor with oral administration of 5-aminolevulinic acid. We conducted a re-analysis of perioperative hypotension in...
10.
Kano H, Kadono Y, Naito R, Makino T, Iwamoto H, Yaegashi H, et al.
Cancers (Basel)
. 2024 Apr;
16(7).
PMID: 38610982
Background: The efficacy of intermittent androgen deprivation therapy (ADT) for biochemical recurrence (BCR) after robot-assisted radical prostatectomy (RARP) is unknown, and its usefulness in Japanese practice needs to be investigated....